Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data

Limited data are available on the responses to heterologous vaccine regimens for SARS-CoV-2, especially among countries using inactivated and adenoviral-vectored vaccines. A total of 77 participants who received heterologous inactivated COVID-19 vaccine (CoronaVac) and adenoviral-vectored vaccine (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanlapakorn, Nasamon, Suntronwong, Nungruthai, Phowatthanasathian, Harit, Yorsaeng, Ritthideach, Thongmee, Thanunrat, Vichaiwattana, Preeyaporn, Auphimai, Chompoonut, Wongsrisang, Lakkhana, Klinfueng, Sirapa, Sudhinaraset, Natthinee, Poovorawan, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013645/
https://www.ncbi.nlm.nih.gov/pubmed/35465981
http://dx.doi.org/10.1016/j.vaccine.2022.04.043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013645/
https://www.ncbi.nlm.nih.gov/pubmed/35465981
http://dx.doi.org/10.1016/j.vaccine.2022.04.043

Ejemplares similares